Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stress Disorders, Post-Traumatic | 17 | 2025 | 651 | 2.940 |
Why?
|
| Depressive Disorder, Major | 10 | 2025 | 473 | 2.680 |
Why?
|
| Ketamine | 13 | 2023 | 226 | 2.510 |
Why?
|
| Hallucinogens | 7 | 2025 | 51 | 2.290 |
Why?
|
| Glutamic Acid | 4 | 2024 | 209 | 1.250 |
Why?
|
| Connectome | 4 | 2025 | 118 | 1.210 |
Why?
|
| Veterans | 9 | 2023 | 1788 | 1.060 |
Why?
|
| Ibogaine | 2 | 2023 | 2 | 1.050 |
Why?
|
| Suicidal Ideation | 4 | 2025 | 254 | 0.970 |
Why?
|
| Stress, Psychological | 3 | 2020 | 604 | 0.940 |
Why?
|
| Antidepressive Agents | 11 | 2023 | 327 | 0.850 |
Why?
|
| Nerve Net | 3 | 2025 | 259 | 0.840 |
Why?
|
| Synaptic Transmission | 3 | 2020 | 365 | 0.790 |
Why?
|
| Brain | 5 | 2025 | 3226 | 0.740 |
Why?
|
| Laburnum | 1 | 2019 | 2 | 0.650 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 48 | 0.620 |
Why?
|
| Neurobiology | 2 | 2020 | 25 | 0.610 |
Why?
|
| Health Surveys | 1 | 2019 | 262 | 0.580 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 188 | 0.540 |
Why?
|
| Resilience, Psychological | 1 | 2018 | 76 | 0.520 |
Why?
|
| Cognition | 2 | 2019 | 819 | 0.510 |
Why?
|
| Prefrontal Cortex | 5 | 2024 | 218 | 0.490 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 897 | 0.490 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 317 | 0.460 |
Why?
|
| Military Personnel | 3 | 2022 | 204 | 0.440 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 2025 | 20 | 0.420 |
Why?
|
| Excitatory Amino Acid Antagonists | 3 | 2019 | 99 | 0.400 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 2 | 2023 | 128 | 0.340 |
Why?
|
| Psychotherapy | 2 | 2025 | 247 | 0.340 |
Why?
|
| Cerebral Cortex | 3 | 2018 | 482 | 0.320 |
Why?
|
| Neural Pathways | 2 | 2025 | 283 | 0.320 |
Why?
|
| Humans | 37 | 2025 | 134225 | 0.310 |
Why?
|
| Suicide | 2 | 2023 | 204 | 0.300 |
Why?
|
| Antigen Presentation | 1 | 2007 | 117 | 0.260 |
Why?
|
| Adult | 15 | 2025 | 31962 | 0.260 |
Why?
|
| Touch | 1 | 2025 | 39 | 0.220 |
Why?
|
| Male | 18 | 2025 | 66215 | 0.220 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2022 | 173 | 0.210 |
Why?
|
| Methoxydimethyltryptamines | 1 | 2023 | 1 | 0.210 |
Why?
|
| Dendritic Cells | 1 | 2007 | 449 | 0.210 |
Why?
|
| Neurotransmitter Agents | 1 | 2024 | 150 | 0.210 |
Why?
|
| Middle Aged | 10 | 2025 | 29430 | 0.200 |
Why?
|
| Mexico | 1 | 2023 | 190 | 0.200 |
Why?
|
| Sirolimus | 2 | 2022 | 239 | 0.200 |
Why?
|
| Glutamates | 2 | 2023 | 70 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 373 | 0.190 |
Why?
|
| Drugs, Investigational | 1 | 2022 | 24 | 0.190 |
Why?
|
| Depression | 3 | 2023 | 1365 | 0.190 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2020 | 307 | 0.180 |
Why?
|
| Pilot Projects | 3 | 2023 | 1493 | 0.180 |
Why?
|
| Combat Disorders | 1 | 2021 | 22 | 0.180 |
Why?
|
| Machine Learning | 1 | 2025 | 344 | 0.180 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2022 | 149 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2025 | 3869 | 0.180 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2024 | 174 | 0.170 |
Why?
|
| Alcoholism | 1 | 2023 | 253 | 0.170 |
Why?
|
| Mental Disorders | 2 | 2019 | 890 | 0.160 |
Why?
|
| Female | 14 | 2025 | 72054 | 0.160 |
Why?
|
| Norepinephrine | 2 | 2018 | 175 | 0.150 |
Why?
|
| Neuroimaging | 2 | 2019 | 376 | 0.150 |
Why?
|
| Young Adult | 6 | 2025 | 9963 | 0.150 |
Why?
|
| Executive Function | 1 | 2019 | 126 | 0.150 |
Why?
|
| Locus Coeruleus | 1 | 2018 | 21 | 0.140 |
Why?
|
| Sympathetic Nervous System | 1 | 2018 | 67 | 0.140 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 72 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 154 | 0.130 |
Why?
|
| Receptors, Glutamate | 1 | 2016 | 18 | 0.130 |
Why?
|
| Caudate Nucleus | 1 | 2016 | 37 | 0.130 |
Why?
|
| Self Report | 1 | 2019 | 553 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 1251 | 0.120 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2015 | 38 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2018 | 484 | 0.110 |
Why?
|
| Amygdala | 1 | 2015 | 87 | 0.110 |
Why?
|
| Alleles | 1 | 2019 | 1724 | 0.110 |
Why?
|
| United States | 4 | 2025 | 11798 | 0.100 |
Why?
|
| Cerebellum | 1 | 2016 | 467 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2019 | 5225 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2023 | 6617 | 0.100 |
Why?
|
| Aged | 3 | 2025 | 21822 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2022 | 571 | 0.080 |
Why?
|
| Hippocampus | 1 | 2015 | 864 | 0.080 |
Why?
|
| Adolescent | 2 | 2025 | 20647 | 0.080 |
Why?
|
| Emotions | 2 | 2023 | 365 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3509 | 0.070 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2007 | 25 | 0.070 |
Why?
|
| B7-2 Antigen | 1 | 2007 | 16 | 0.070 |
Why?
|
| HLA-DR Antigens | 1 | 2007 | 71 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2022 | 1666 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2007 | 122 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2023 | 13105 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2007 | 191 | 0.060 |
Why?
|
| Harm Reduction | 1 | 2025 | 12 | 0.060 |
Why?
|
| Interferon-alpha | 1 | 2007 | 246 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 855 | 0.060 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2024 | 30 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2007 | 824 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2025 | 159 | 0.050 |
Why?
|
| Consciousness | 1 | 2024 | 48 | 0.050 |
Why?
|
| Spirituality | 1 | 2024 | 52 | 0.050 |
Why?
|
| Glutamine | 1 | 2024 | 222 | 0.050 |
Why?
|
| Psilocybin | 1 | 2022 | 9 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 37 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 169 | 0.050 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2020 | 12 | 0.040 |
Why?
|
| Biomarkers | 2 | 2023 | 3434 | 0.040 |
Why?
|
| Psychometrics | 1 | 2023 | 690 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1628 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 296 | 0.040 |
Why?
|
| Gyrus Cinguli | 1 | 2019 | 135 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2023 | 897 | 0.040 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 154 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 153 | 0.040 |
Why?
|
| Arousal | 1 | 2016 | 82 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1735 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 109 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 757 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 239 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 616 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1222 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2016 | 405 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 855 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 3056 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2018 | 815 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 3719 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 393 | 0.020 |
Why?
|
| Risk Factors | 1 | 2023 | 11196 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3759 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 36526 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 4611 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17591 | 0.010 |
Why?
|